{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:11:26Z","timestamp":1791886286093,"version":"4.3.4"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Endothelin receptor antagonists are first-line therapy for pulmonary arterial hypertension (PAH). The first 2 agents approved in the class, bosentan and ambrisentan, initially carried boxed warnings for hepatotoxicity and required monthly liver function tests (LFTs) as part of a risk evaluation and mitigation strategy (REMS); however, in 2011, as further safety data emerged on ambrisentan, the boxed hepatotoxicity warning and LFT requirements were removed.<\/jats:p><\/jats:sec>Objective<\/jats:title>To analyze changes in the use of and LFT monitoring for ambrisentan and bosentan after changes to the ambrisentan labeling and REMS.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This serial cross-sectional study used data from 3 longitudinal health care insurance claims databases\u2014Medicaid, Optum\u2019s deidentified Clinformatics Data Mart, and Merative Marketscan\u2014to perform an interrupted time series analysis of prescription fills and LFTs for patients taking ambrisentan and bosentan. Participants were patients filling prescriptions for ambrisentan and bosentan from July 1, 2007, to December 31, 2018. Data analysis was performed from April 2021 to August 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Removal of the boxed warning for hepatotoxicity and the REMS LFT monitoring requirements on ambrisentan in March 2011.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were use of ambrisentan (ie, individuals with at least 1 dispensing per 1\u202f000\u202f000 individuals enrolled in the 3 datasets) vs bosentan and LFT monitoring (ie, proportion of initiators with at least 1 ordered test) before initiation and before the first refill.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 10\u202f261 patients received a prescription for ambrisentan during the study period (7442 women [72.5%]; mean [SD] age, 52.6 [17.6] years), and 11\u202f159 patients received a prescription for bosentan (7931 women [71.1%]; mean [SD] age, 47.7 [23.7] years). Removal of the ambrisentan boxed hepatotoxicity warning and LFT monitoring requirement was associated with an immediate increase in the use of ambrisentan (1.50 patients per million enrollees; 95% CI, 1.08 to 1.92 patients per million enrollees) but no significant change in the use of bosentan. There were reductions in recorded LFTs before drug initiation (13.1% absolute decrease; 95% CI, \u221218.2% to \u22128.0%) and before the first refill (26.4% absolute decrease; 95% CI, \u221234.4% to \u221218.5%) of ambrisentan but not bosentan.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this serial cross-sectional study of ambrisentan, labeling changes and removal of the REMS-related LFT requirement were associated with shifts in prescribing and testing behavior for ambrisentan but not bosentan. Further clinician education may be needed to maximize the benefits of REMS programs and labeling warnings designed to ensure the safe administration of high-risk medications.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.19873","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:02:10Z","timestamp":1721314930000},"page":"e2419873","source":"Crossref","is-referenced-by-count":7,"title":["Removing the FDA\u2019s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan"],"prefix":"10.1001","volume":"7","author":[{"given":"William B.","family":"Feldman","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mahesri","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Sarpatwari","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Been","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama","family":"Kattinakere Sreedhara","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita A.","family":"Toyserkani","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zendel","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"LaCivita","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Manzo","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Dal Pan","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"3","key":"zoi240641r1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report.","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"issue":"2","key":"zoi240641r2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1183\/09031936.00078207","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension.","volume":"31","author":"Dupuis","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"zoi240641r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub6","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension.","volume":"3","author":"Liu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9288","key":"zoi240641r5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"zoi240641r6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240641r7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension.","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"issue":"3","key":"zoi240641r8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1183\/09031936.00094409","article-title":"Liver toxicity: the Achilles\u2019 heel of endothelin receptor antagonist therapy?","volume":"34","author":"Hoeper","year":"2009","journal-title":"Eur Respir J"},{"issue":"12","key":"zoi240641r10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1803910","article-title":"The FDA Amendments Act of 2007: assessing its effects a decade later.","volume":"379","author":"Avorn","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi240641r11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-021-01070-2","article-title":"A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs.","volume":"44","author":"Sarpatwari","year":"2021","journal-title":"Drug Saf"},{"issue":"4","key":"zoi240641r15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics.","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"zoi240641r17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"zoi240641r18","doi-asserted-by":"publisher","DOI":"10.7573\/17404398","article-title":"Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function.","volume":"4","author":"Blanchette","year":"2015","journal-title":"Drugs Context"},{"key":"zoi240641r4","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed September 8, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"zoi240641r9","unstructured":"US Food and Drug Administration. Risk evaluation and mitigation strategies: REMS. Accessed April 12, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems"},{"key":"zoi240641r12","unstructured":"US Food and Drug Administration. Bosentan risk evaluation and mitigation strategy (REMS). Accessed April 12, 2024. https:\/\/bosentanremsprogram.com\/#Main"},{"key":"zoi240641r13","unstructured":"US Food and Drug Administration. The ambrisentan REMS (risk evaluation and mitigation strategy). Accessed April 12, 2024. https:\/\/ambrisentanrems.us.com\/#Main"},{"key":"zoi240641r14","unstructured":"US Food and Drug Administration. FDA drug safety communication: liver injury warning to be removed from Letairis (ambrisentan) tablets. Accessed April 12, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-liver-injury-warning-be-removed-letairis-ambrisentan-tablets"},{"key":"zoi240641r16","unstructured":"Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Accessed April 12, 2024. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2821343\/feldman_2024_oi_240641_1720720455.38471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:02:13Z","timestamp":1721314933000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2821343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.19873","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}